Special Issue

Marine-Derived Antibiotics

Message from the Guest Editors

Metabolites produced by marine organisms represent a novel resource of bioactive molecules with therapeutic potential, characterized by the chemical and biological diversity of the vast and partly unknown marine environment. Marine secondary metabolites are selected in Nature to perform specialized defense functions, including bacterial inhibition. However, their scarce amounts often prevent full biological investigation and application. Marine natural products can be sources of new antibiotics. Enhancing their biogenetic production and optimizing isolation and identification procedures can improve their role in drug development. Organic synthesis provides suitable amounts of natural antibacterial hits and analogs with more favorable drug-likeness. Prediction of physico-chemical properties and docking calculations help select the most promising Nature-inspired antibiotic structures. This Special Issue welcomes original research articles, reviews, and short communications discussing advances in these and related approaches.

Guest Editors

Prof. Dr. Ines Mancini

Bioorganic Chemistry Laboratory, Department of Physics, University of Trento, Via Sommarive 14, I-38123 Povo-Trento, Italy

Dr. Andrea Defant

Bioorganic Chemistry Laboratory, Department of Physics, University of Trento, Via Sommarive 14, I-38123 Povo-Trento, Italy

Deadline for manuscript submissions

30 June 2026

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 10.2
Indexed in PubMed

mdpi.com/si/256760

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 10.2
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI